Quarterly report pursuant to Section 13 or 15(d)

SEGMENTS (Details)

v3.20.2
SEGMENTS (Details) - USD ($)
 3 Months Ended 6 Months Ended 193 Months Ended
Jun. 30, 2020
Mar. 31, 2020
Jun. 30, 2019
Mar. 31, 2019
Jun. 30, 2020
Jun. 30, 2019
Jun. 30, 2020
Revenues $ 7,787,594   $ 6,560,942   $ 17,987,338 $ 10,089,531  
Cost of product revenue 13,495,629   10,491,236   30,324,855 19,896,415  
Loss from operations (17,123,825)   (11,338,674)   (33,893,611) (24,547,090)  
Gain on transfer of plasma center assets 0   0   0 11,527,421  
Loss on the extinguishment of debt 0   0   0 9,962,495  
Net loss (20,178,091) $ (19,245,230) (13,211,872) $ (13,067,955) (39,423,321) (26,279,827) $ 304,100,000
Depreciation and amortization expense         1,674,490 1,611,422  
Consolidated (member)              
Revenues 7,787,594   6,560,942   17,987,338 10,089,531  
Cost of product revenue 13,495,629   10,491,236   30,324,855 19,896,415  
Loss from operations (17,123,825)   (11,338,674)   (33,893,611) (24,547,090)  
Interest and other expense, net (3,054,266)   (1,873,198)   (5,529,710) (3,297,663)  
Gain on transfer of plasma center assets 0         11,527,421  
Loss on the extinguishment of debt           (9,962,495)  
Net loss (20,178,091)   (13,211,872)   (39,423,321) (26,279,827)  
Capital expenditure 6,243,284       6,243,284 245,675  
Depreciation and amortization expense 885,652   806,093   1,674,490 1,611,422  
TOTAL ASSETS 191,541,568   143,274,120        
Plasma Collection Centers              
Revenues 1,249,020   2,522,788   3,669,782 4,671,686  
Cost of product revenue 1,258,488   2,320,855   3,635,761 3,785,688  
Loss from operations (919,309)   (392,181)   (1,376,464) (362,601)  
Interest and other expense, net (33)   (59)   (33) 13,560  
Gain on transfer of plasma center assets 0   0     11,527,421  
Loss on the extinguishment of debt 0   0        
Net loss (919,342)   (392,240)   (1,376,497) 11,178,380  
Capital expenditure         1,178,790 21,235  
Depreciation and amortization expense 111,106   113,958   222,395 228,199  
TOTAL ASSETS 7,542,486   3,835,999        
Corporate              
Revenues 35,709   35,709   71,417 71,417  
Cost of product revenue 0   0        
Loss from operations (3,351,681)   (2,274,710)   (7,188,167) (4,891,898)  
Interest and other expense, net (2,818,791)   (1,626,536)   (5,055,363) (2,895,007)  
Gain on transfer of plasma center assets 0   0        
Loss on the extinguishment of debt           (9,962,495)  
Net loss (6,170,472)   (3,901,246)   (12,243,530) (17,749,400)  
Capital expenditure 0   0   6,243,284 245,675  
Depreciation and amortization expense 2,305   3,287   4,881 6,983  
TOTAL ASSETS 74,893,664   72,201,705        
ADMA BioManufacturing              
Revenues 6,502,865   4,002,445   14,246,139 5,346,428  
Cost of product revenue 12,237,141   8,170,381   26,689,094 16,110,727  
Loss from operations (12,852,835)   (8,671,783)   (25,328,980) (19,292,591)  
Interest and other expense, net (235,442)   (246,603)   (474,314) (416,216)  
Gain on transfer of plasma center assets 0   0        
Net loss (13,088,277)   (8,918,386)   (25,803,294) (19,708,807)  
Capital expenditure         5,064,494 224,440  
Depreciation and amortization expense 772,241   688,848   $ 1,447,214 $ 1,376,240  
TOTAL ASSETS $ 109,105,418   $ 67,236,416